Table 1 Correlation of HDL parameters to apoB-lipoprotein indicators for the total cohort excluding one CETP mutation homozygote and one CETP normal male with TG 1438 mg/dL (n = 312). ApoB-lipoprotein parameters are treated in a logarithmic scale except for nonHDL-C
From: ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
y | x | Regression | r2 | p |
|---|---|---|---|---|
HDL-C | apoB | y = −24.13 ln(x) + 169.01 | 0.21634 | < 0.0001 |
|  | TG | y = −17.07 ln(x) + 136.57 | 0.31917 | < 0.0001 |
|  | nonHDL-C | y = −0.1536 x + 77.838 | 0.11965 | < 0.0001 |
|  | TG + nonHDL-C | y = −24.5 ln(x) + 191.47 | 0.28738 | < 0.0001 |
apoA-I | apoB | y = −8.3 ln(x) + 198.88 | 0.00687 | 0.1442 |
|  | TG | y = −7.434 ln(x) + 195 | 0.01625 | 0.0243 |
|  | nonHDL-C | y = −0.0514 × + 167.33 | 0.0036 | 0.2906 |
|  | TG + nonHDL-C | y = −10.59 ln(x) + 218.45 | 0.0144 | 0.0341 |
apoA-II | apoB | y = 6.9568 ln(x) + 4.8902 | 0.10358 | < 0.0001 |
|  | TG | y = 3.5411 ln(x) + 20.668 | 0.07915 | < 0.0001 |
|  | nonHDL-C | y = 0.0522 × + 30.102 | 0.07973 | < 0.0001 |
|  | TG + nonHDL-C | y = 5.8489 ln(x) + 5.0808 | 0.09432 | < 0.0001 |
apoA-I in LpAI | apoB | y = −23.52 ln(x) + 161.98 | 0.15871 | < 0.0001 |
|  | TG | y = −15.1 ln(x) + 123.19 | 0.19289 | < 0.0001 |
|  | nonHDL-C | y = −0.1628 × + 74.852 | 0.10373 | < 0.0001 |
|  | TG + nonHDL-C | y = −22.9 ln(x) + 178.46 | 0.19376 | < 0.0001 |
apoA-I in LpAI:AII | apoB | y = 15.223 ln(x) + 36.899 | 0.04736 | 0.0001 |
|  | TG | y = 7.6666 ln(x) + 71.809 | 0.03542 | 0.0008 |
|  | nonHDL-C | y = 0.1113 × + 92.476 | 0.03456 | 0.0010 |
|  | TG + nonHDL-C | y = 12.312 ln(x) + 39.988 | 0.0399 | 0.0004 |